Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. ECI Pharmaceuticals, LLC
WARNING LETTER
•ECI Pharmaceuticals, LLC•March 22, 2022

ECI Pharmaceuticals, LLC – FDA Warning Letter, Mar 22, 2022

Record Details

The FDA issued a Warning Letter to John Copanos regarding drug listing deficiencies for "esterified estrogens and methyltestosterone" (NDC 51293-639 and 51293-640). The review of the firm’s electronic Drug Registration and Listing System (eDRLS) submission revealed an incorrect active ingredient selection.

Specifically, the electronic listing file for both products incorrectly listed "conjugated estrogens" as the active ingredient, while the accompanying labeling correctly identified "esterified estrogens." These are distinct and non-equivalent active ingredients. This constitutes a violation of Section 510(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), which requires firms to include the correct name and quantity of each active pharmaceutical ingredient in the listing. This is a prohibited act under Section 301(p) of the FD&C Act.

Furthermore, the failure to properly list the drug renders it misbranded under Section 502(o) and in violation of Section 301(a) of the FD&C Act. The FDA had previously notified the firm of these deficiencies on October 26, 2021, and subsequently removed the products from the FDA’s Online NDC Directory on December 10, 2021, due to continued non-compliance.

The FDA emphasizes that accurate registration and listing information is crucial for patient safety, drug establishment inspections

Company
ECI Pharmaceuticals, LLC
Inspection date
March 22, 2022
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Carolyn E. Becker
View Company Profile

ID · ba249f39-27ff-4445-a618-e86838030f85

Violation Codes8
FD&C Act 510(j)21 CFR 20721 U.S.C. 360(j)21 U.S.C. 331(p)FD&C Act 502(o)FD&C Act 301(a)21 U.S.C. 352(o)21 U.S.C. 331(a)

Full citation text and observation details available on the Dashboard.

Other documents for ECI Pharmaceuticals, LLC
  • 483 - 2023-01-27January 27, 2023
  • WARNING_LETTER - 2022-02-15February 15, 2022
  • 483 - 2016-11-18November 18, 2016
  • 483 - 2015-02-27February 27, 2015

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore ECI Pharmaceuticals, LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.